Zhenggang Ren

机构：Sun Yat-sen University, Fudan University, National Clinical Research Center for Digestive Diseases, Zhongshan Hospital, The First Affiliated Hospital, Sun Yat-sen University, Ministry of Education · ORCID：0000-0002-2799-547X

发表论文 50 篇 · 总被引 2727 次 · h-index 21

代表论文

• Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial (2023 · The Lancet · 被引 1109)
• Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study (2023 · Signal Transduction and Targeted Therapy · 被引 156)
• Camrelizumab plus oxaliplatin‐based chemotherapy as first‐line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial (2021 · International Journal of Cancer · 被引 49)
• Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial (2024 · Journal of Clinical Oncology · 被引 36)
• Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment (2022 · Cellular and Molecular Gastroenterology and Hepatology · 被引 33)
• A glucose-enriched lung pre-metastatic niche triggered by matrix stiffness-tuned exosomal miRNAs in hepatocellular carcinoma (2025 · Nature Communications · 被引 32)